Biotech Values

[exwannabe]

Re: Worst Bio exec '08

Can we nominate scamsters? If so Nance of INGN leads the field.

Other than that, Bruce Carter (ZGEN) gets a nod for trying to set up a marketing arm for RecoThrombin. If he had just sold the drug after FDA thumbs up, the stock would not have been slammed by the slow sales (and it's also possible sales would have ramped up faster, I doubt semi partner Bayer cares much).

One could say this is monday morning QBing, but even at the time many wondered why a pure R&D outfit would try and market a drug themselves (even with help).